The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Other Investors | Alive

About Immune Cell Therapy

ICT is developing a personalized vaccine treatment to help cancer from recurring. A small amount of the patient's own primary tumor is used to prepare the vaccine, so that the vaccine targets the specific cancer that the patient has. This personalized vaccine is much simpler and cheaper to produce than existing cancer vaccine therapies that are being tested. ICT has received approval from the FDA for its IND to begin clinical trials for lung cancer, which will initially be conducted at the University of Pittsburgh.

Immune Cell Therapy Headquarter Location

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Immune Cell Therapy

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Immune Cell Therapy is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest Immune Cell Therapy News

CellOrigin Closed a New Round of Investment to Jump-start its iPSC Immune Cell Therapy Products Toward Clinics

Mar 29, 2022

Intellasia East Asia News 29-Mar-2022 Intellasia | PR Newswire Asia | 7:50 PM HANGZHOU, China, March 29, 2022 /PRNewswire/ -- On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of investment of ~100 million RMB from Jifeng Ventures, Kunlun Capital, Yinxinggu Capital and Efung Capital. CellOrigin is committed to develop engineered iPSC-derived CAR-macrophage and CAR-NK cell product. Integrating single cell atlas of differentiation, AI and synthetic biology approaches, CellOrigin developed its technology platform to learn from developmental biology in order to optimize more efficient differentiation methods, and to design more effective cell products. Building on its proprietary technology platform of engineering macrophage and DC cells through iPSCs, CellOrigin aims to make engineered clonal iPSC-derived off-the-shelf immune cell products in large scale for cancer immunotherapy applications. The founding members of the CellOrigin team have rich experiences in cell therapies in academia and industry. The scientific co-founder Dr. Jin Zhang is a principal investigator at Zhejiang University, and was trained at the Boston Children's Hospital/Harvard Medical School before he joined the university in 2017. His team for the first time reported the iPSC-derived CAR-macrophage or CAR-iMac. He is fully committed to enable the next generation of innovative cell products with the continuous input of research on developmental biology and new disruptive technologies. Dr.Jiansong Tong joined CellOrigin as a co-founder and CEO in September,2021. After received his Ph.D. from Iowa State University, he went to the Scripps Research Institute to begin his postdoc study on the genetic diseases such as cystic fibrosis etc. by applying gene therapy methods. In 2015, he started his industry career at the Sorrento Therapeutics as a Research Scientist of CAR-T cell therapy. Later 2017, he joined well-known domestic pharmaceutical companies as Director/Head of Cell Therapy Department responsible for UCAR-T cell product development. He has tremendous experiences on antibody discovery, R&D, process development, and cGMP manufacture of CAR-T cell, as well as assay development and quality control system. CellOrigin has a strong belief in the advantages and promise brought by iPSC + synthetic biology for the next generation of cell therapy product. Its proprietary innate immune cell CAR-iMac differentiation and engineering method has secured patents in China and Australia, and started the process to enter the US and other countries. More proprietary designs related to phagocytosis, polarization and other features of innate immune cells will be cumulatively integrated to CellOrigin's pipeline. Led by a professional CMC team with rich experiences in cell therapies, these products will be manufactured at CellOrigin's "B+A" GMP facility at Hangzhou, and move forward to clinical trials this year to bring benefits to patients.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.